| Natural history of adult ulcerative colitis in population-based cohorts: a systematic review M Fumery, S Singh, PS Dulai, C Gower-Rousseau, L Peyrin-Biroulet, ... Clinical Gastroenterology and Hepatology 16 (3), 343-356. e3, 2018 | 434 | 2018 |
| Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study C Charpentier, J Salleron, G Savoye, M Fumery, V Merle, JE Laberenne, ... Gut 63 (3), 423-432, 2014 | 410 | 2014 |
| Innate mucosal-associated invariant T (MAIT) cells are activated in inflammatory bowel diseases NE Serriari, M Eoche, L Lamotte, J Lion, M Fumery, P Marcelo, ... Clinical & Experimental Immunology 176 (2), 266-274, 2014 | 353 | 2014 |
| First-and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis S Singh, MH Murad, M Fumery, PS Dulai, WJ Sandborn Clinical Gastroenterology and Hepatology 18 (10), 2179-2191. e6, 2020 | 318 | 2020 |
| Epidemiology of inflammatory bowel diseases: new insights from a French population-based registry (EPIMAD) C Gower-Rousseau, F Vasseur, M Fumery, G Savoye, J Salleron, ... Digestive and Liver Disease 45 (2), 89-94, 2013 | 255 | 2013 |
| Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study Y Bouhnik, F Carbonnel, D Laharie, C Stefanescu, X Hébuterne, V Abitbol, ... Gut 67 (1), 53-60, 2018 | 254 | 2018 |
| Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study J Burisch, G Kiudelis, L Kupcinskas, HAL Kievit, KW Andersen, ... Gut 68 (3), 423-433, 2019 | 249 | 2019 |
| Systematic review with network meta‐analysis: first‐and second‐line pharmacotherapy for moderate‐severe ulcerative colitis S Singh, M Fumery, WJ Sandborn, MH Murad Alimentary pharmacology & therapeutics 47 (2), 162-175, 2018 | 248 | 2018 |
| Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies M Fumery, C Xiaocang, L Dauchet, C Gower-Rousseau, L Peyrin-Biroulet, ... Journal of Crohn's and Colitis 8 (6), 469-479, 2014 | 242 | 2014 |
| Systematic review and network meta‐analysis: first‐and second‐line biologic therapies for moderate‐severe Crohn's disease S Singh, M Fumery, WJ Sandborn, MH Murad Alimentary pharmacology & therapeutics 48 (4), 394-409, 2018 | 210 | 2018 |
| Comparative acceptability and perceived clinical utility of monitoring tools: a nationwide survey of patients with inflammatory bowel disease A Buisson, F Gonzalez, F Poullenot, S Nancey, E Sollellis, M Fumery, ... Inflammatory bowel diseases 23 (8), 1425-1433, 2017 | 191 | 2017 |
| Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn’s disease refractory to anti–tumor necrosis factor agents P Wils, Y Bouhnik, P Michetti, B Flourie, H Brixi, A Bourrier, M Allez, ... Clinical Gastroenterology and Hepatology 14 (2), 242-250. e2, 2016 | 180 | 2016 |
| Dramatic increase in incidence of ulcerative colitis and Crohn's disease (1988–2011): a population-based study of French adolescents S Ghione, H Sarter, M Fumery, L Armengol-Debeir, G Savoye, D Ley, ... Official journal of the American College of Gastroenterology| ACG 113 (2 …, 2018 | 175 | 2018 |
| Deep remission at 1 year prevents progression of early Crohn’s disease RC Ungaro, C Yzet, P Bossuyt, FJ Baert, T Vanasek, GR D’Haens, ... Gastroenterology 159 (1), 139-147, 2020 | 173 | 2020 |
| Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis S Singh, MH Murad, M Fumery, R Sedano, V Jairath, R Panaccione, ... The Lancet Gastroenterology & Hepatology 6 (12), 1002-1014, 2021 | 160 | 2021 |
| Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab D Laharie, A Bourreille, J Branche, M Allez, Y Bouhnik, J Filippi, F Zerbib, ... Gut 67 (2), 237-243, 2018 | 159 | 2018 |
| Postoperative complications after ileocecal resection in Crohn’s disease: a prospective study from the REMIND group M Fumery, P Seksik, C Auzolle, N Munoz-Bongrand, JM Gornet, ... Official journal of the American College of Gastroenterology| ACG 112 (2 …, 2017 | 158 | 2017 |
| Systematic review: fertility in non‐surgically treated inflammatory bowel disease N Tavernier, M Fumery, L Peyrin‐Biroulet, JF Colombel, ... Alimentary pharmacology & therapeutics 38 (8), 847-853, 2013 | 155 | 2013 |
| Incidence, risk factors, and outcomes of colorectal cancer in patients with ulcerative colitis with low-grade dysplasia: a systematic review and meta-analysis M Fumery, PS Dulai, S Gupta, LJ Prokop, S Ramamoorthy, WJ Sandborn, ... Clinical Gastroenterology and Hepatology 15 (5), 665-674. e5, 2017 | 149 | 2017 |
| Natural disease course of ulcerative colitis during the first five years of follow-up in a European population-based inception cohort—an Epi-IBD study J Burisch, KH Katsanos, DK Christodoulou, L Barros, F Magro, ... Journal of Crohn's and Colitis 13 (2), 198-208, 2019 | 148 | 2019 |
